Get the Stockscreener App
133.02
0.54%
-0.72
After Hours:
133.30
0.28
+0.21%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $133.02, with a volume of 4.82M.
It is down -0.54% in the last 24 hours and up +0.06% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$133.74
Open:
$134.085
24h Volume:
4.82M
Relative Volume:
0.78
Market Cap:
$231.52B
Revenue:
$43.11B
Net Income/Loss:
$13.94B
P/E Ratio:
16.64
EPS:
7.9963
Net Cash Flow:
$6.78B
1W Performance:
-0.69%
1M Performance:
+0.06%
6M Performance:
+6.54%
1Y Performance:
+17.34%
1-Day Range:
$131.93
$134.09
1-Week Range:
$129.08
$135.45
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
133.02 | 232.77B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.90 | 143.29B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.24 | 140.03B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
98.33 | 126.25B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
76.72 | 44.95B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Evercore ISI Adjusts Abbott Laboratories Price Target to $144 From $140, Maintains Outperform Rating - MarketScreener
Abbott Laboratories' (NYSE:ABT) Returns On Capital Are Heading Higher - Yahoo
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology - Zacks Investment Research
Thyroid Cancer Diagnostics Market Size to Surge USD 5.22 Billion at 5.34% CAGR by 2034 - GlobeNewswire Inc.
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Is Abbott Laboratories (ABL) stock positioned for secular growthPortfolio Update Summary & Low Drawdown Trading Strategies - newser.com
What candlestick patterns are forming on Abbott LaboratoriesMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Top Stock Reports for AMD, Abbott & Micron Technology - The Globe and Mail
Abbott (ABT) Laps the Stock Market: Here's Why - Yahoo Finance
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories (ABT): Exploring Valuation as Steady Gains Draw Investor Interest in 2024 - simplywall.st
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True? - Yahoo
‘Few missions more meaningful than improving global health,’ says HR expert - Silicon Republic
Why analysts recommend Abbott Laboratories (ABL) stockJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Ready To Pass On Abbott Laboratories (NYSE:ABT)? Think Again - 富途牛牛
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook - Insider Monkey
2 Profitable Stocks to Consider Right Now and 1 We Find Risky - FinancialContent
Abbott Laboratories Q3 Earnings Preview: Profit boost expected - MSN
Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale - MSN
Europe Clinical Nutrition Market to hit US$ 36.63 Billion by 2033 - openPR.com
Will Abbott Laboratories (Common Stock) (ABL0) stock attract long term capital inflowsJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $157 From $153, Maintains Buy Rating - MarketScreener
Abbott (ABT) Gains Attention with Inclusion in Goldman Sachs Con - GuruFocus
Will Abbott Laboratories (ABL) stock return to pre crash levelsJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Abbott wins Health Canada approval for Esprit drug-eluting, dissolving scaffold - MassDevice
Union Bancaire Privee UBP SA Sells 30,201 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT is Paradiem LLC's 5th Largest Position - MarketBeat
Synlait to sell North Island assets to Abbott for $178m - FoodBev Media
Health Canada authorises Abbott’s Esprit BTK system for CLTI treatment - Medical Device Network
HB Wealth Management LLC Cuts Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Janney Montgomery Scott LLC - MarketBeat
How buyback programs support Abbott Laboratories stockMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
How Abbott Laboratories stock responds to policy changesJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
Synlait Milk agrees North Island asset sale to Abbott Laboratories - Global Food Industry News
Strategies to average down on Abbott LaboratoriesRecession Risk & AI Based Buy and Sell Signals - newser.com
Abbott Laboratories (ABT): A Healthcare Leader Offering Dividend Value and Growth - MSN
Can swing trading help recover from Abbott Laboratories lossesMarket Weekly Review & Target Return Focused Picks - newser.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Detecting support and resistance levels for Abbott LaboratoriesMarket Activity Recap & Weekly Sector Rotation Insights - newser.com
NZ's Synlait cuts annual loss, inks asset sale deal; shares surge - Reuters
Smith Chas P & Associates PA Cpas Sells 2,167 Shares of Abbott Laboratories $ABT - MarketBeat
GC Wealth Management RIA LLC Grows Position in Abbott Laboratories $ABT - MarketBeat
Klein Pavlis & Peasley Financial Inc. Acquires Shares of 17,000 Abbott Laboratories $ABT - MarketBeat
What to Expect From Abbott Laboratories' Next Quarterly Earnings Report - Yahoo Finance
Moody Lynn & Lieberson LLC Sells 12,285 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Fort Washington Investment Advisors Inc. OH - MarketBeat
Can volume confirm reversal in Abbott Laboratories2025 Fundamental Recap & Real-Time Market Sentiment Alerts - newser.com
China’s Bright Dairy to Sell New Zealand Assets to Abbott for USD170 Million - 一财全球Yicai Global
Synlait Milk reports full-year loss ahead of asset sale - RNZ
Synlait sells Pōkeno site for $307m, manufacturing woes batter bottom line - ThePost.co.nz
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):